Darlene Dobkowski, MA

The recent FDA approval of Talvey for heavily pretreated multiple myeloma results in an improved response to therapy and a manageable side effect profile.

Patients with nonmetastatic node-positive bladder cancer may have similar survival rates whether they underwent treatment with surgery or radical dose radiotherapy.

Reporting MPN side effects to the care team, regardless of how “little” they may seem, can help determine how to adjust treatment to address these symptoms, an expert said.

Cancer teams can decode and analyze DNA from a patient’s tumor to diagnose the disease, determine personalized treatment plans and assess the response to treatment.

Men with prostate cancer who participated in group-based resistance and aerobic exercise regimens had improved sexual function compared with those who underwent usual care.

The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy.

Akeega, the first dual action tablet with a PARP inhibitor and abiraterone acetate, was approved for the treatment of patients with suspected or confirmed BRCA-positive metastatic castration-resistant prostate cancer.

Patients with metastatic clear cell renal cell carcinoma who received corticosteroids during Opdivo treatment did not experience a negative impact on survival.

This regular approval provides Gavreto as a treatment option for patients with metastatic RET fusion-positive non-small cell lung cancer.

Patients with head and neck cancer treated with dysphagia-optimized intensity-modulated radiotherapy had improved swallow function compared with those treated with standard intensity-modulated radiotherapy.

In conjunction with Cancer Champions, CURE® recently hosted the “Educated Patient® Webinar: An Overview of Diet and Exercise in Cancer Care."

Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.

High-level results from a phase 3 trial demonstrated that treatment with batiraxcept did not improve progression-free survival in patients with platinum-resistant ovarian cancer.

Patients with advanced Merkel cell carcinoma treated with Opdivo had improved disease-free survival rates compared with those who underwent observation.

Paul Reubens, who played Pee-Wee Herman since the 1980s, has died from cancer — a diagnosis he decided to keep private.

Recent developments in the use of immunotherapy for lung cancer have provided more treatment options for patients while potentially reducing side effect profiles.

Advancements have been made over the last decade in the use of immunotherapy for the treatment of skin cancers including melanoma, squamous cell carcinoma and Merkel cell carcinoma.

This particular designation may expedite the process of approving Xpovio for the treatment of patients with myelofibrosis to address an unmet medical need.

Patients with Medicaid or no insurance may have worse survival outcomes compared with Medicare or private insurance in those with metastatic renal cell carcinoma.

Palliative care can benefit patients with advanced cancer by integrating advanced care planning, pain and symptom management and counseling, among other aspects.

Adolescents and young adults undergoing VEGF treatment for nonmetastatic, high-risk renal cell carcinoma may still experience heart-related conditions like left ventricular systolic dysfunction and high blood pressure.

Immunotherapy with Opdivo plus cisplatin-based chemotherapy improved overall survival and progression-free survival in patients with unresectable or metastatic urothelial carcinoma.

Fruquintinib improved overall survival compared with placebo in patients with refractory metastatic colorectal cancer.

Reblozyl treatment in patients with anemia from lower-risk myelodysplastic syndromes achieved a greater independence from red blood cell transfusions compared with treatment with epoetin alfa.

If the FDA approves zolbetuximab, this would mark the first CLDN18.2-targeting monoclonal antibody to treat patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Fit patients with chronic lymphocytic leukemia treated with Venclexta and Gazyva, regardless of the use of Imbruvica, experienced improvements in progression-free survival and were more likely to obtain undetectable minimal residual disease.

Patients with advanced cancers who live in states that expanded Medicaid were more likely to receive early palliative care, although utilization remains low in the U.S.

Artificial intelligence was used to develop a predictive biomarker to identify patients with intermediate-risk prostate cancer who would benefit from adding androgen deprivation therapy to radiotherapy.

Patients 65 years and older with NSCLC and undergoing treatment with immunotherapy, chemotherapy and/or targeted therapy were more likely to have worse survival outcomes and declines in activity of daily living.

Findings from a study conducted in women with a history of breast cancer demonstrated that treatment with donepezil, which is typically used to treat symptoms of Alzheimer’s disease and dementia, did not improve cognitive impairment, or “chemo brain.”